Thursday, May 07, 2026 4:59:35 PM
class action lawsuit are just scam from law firms
1. majority of the time you pay $100000 for the lawyer to talk to you and they do nothing billing your $1000/hour for doing research at the nudy bar
2. even if they do something and case has 100% chance of win like motor vehicle accidents the lawyer wants 50% cut.
similitar to SEC fees, company pay the SEC $500,000 just to go public? and SEC doesn't even audit or verify the company assets nowadays $500,000 for what? SEC is now has 1 billion in fines and fees in the bank collected from public companies. how can you trust and organization to regulate anything if the SEC cannot even regulate themselves you know what i mean
and you know why people want to pay $500,000 to SEC just to be listed in the Nasdaq..it's because many firms won't invest in companies not listed in nasdaq and that is only exchange you can short naked. there is no money in the otc market exchange compared to 1990s majority of brokers ban their clients from buying stocks in the otc market now. 99% of customers or demand just vanish just by delisting to the OTC market and no surprise stock crashes 99.99% since there is no bid and no market maker and company is not even bankrupt.
1. majority of the time you pay $100000 for the lawyer to talk to you and they do nothing billing your $1000/hour for doing research at the nudy bar
2. even if they do something and case has 100% chance of win like motor vehicle accidents the lawyer wants 50% cut.
similitar to SEC fees, company pay the SEC $500,000 just to go public? and SEC doesn't even audit or verify the company assets nowadays $500,000 for what? SEC is now has 1 billion in fines and fees in the bank collected from public companies. how can you trust and organization to regulate anything if the SEC cannot even regulate themselves you know what i mean
and you know why people want to pay $500,000 to SEC just to be listed in the Nasdaq..it's because many firms won't invest in companies not listed in nasdaq and that is only exchange you can short naked. there is no money in the otc market exchange compared to 1990s majority of brokers ban their clients from buying stocks in the otc market now. 99% of customers or demand just vanish just by delisting to the OTC market and no surprise stock crashes 99.99% since there is no bid and no market maker and company is not even bankrupt.
Recent AVXL News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
